Role of fusion in radiotherapy treatment planning.
暂无分享,去创建一个
[1] R L Wahl,et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.
[2] Merence Sibomana,et al. Impact of image coregistration with computed tomography (CT), magnetic resonance (MR) and positron emission tomography with fluorodeoxyglucose (FDG-PET) on delineation of GTV’s in oropharyngeal, laryngeal and hypopharyngeal tumors , 2002 .
[3] H. Groen,et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.
[4] C. Degueldre,et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] M. Kris,et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] F Dehdashti,et al. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Valk,et al. Cost-effectiveness of PET imaging in clinical oncology. , 1996, Nuclear medicine and biology.
[8] B J McNeil,et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.
[9] C. Pelizzari,et al. Functional imaging in treatment planning of brain lesions. , 1997, International journal of radiation oncology, biology, physics.
[10] M Teräs,et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. , 2000, International journal of radiation oncology, biology, physics.
[11] P Okunieff,et al. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. , 1994, International journal of radiation oncology, biology, physics.
[12] P. Grigsby,et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. , 2002, International journal of radiation oncology, biology, physics.
[13] N. Gupta,et al. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small ( 3 cm) lymph node lesions. , 2000 .
[14] H. Tonami,et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] M. Schwaiger,et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. , 2002, International journal of radiation oncology, biology, physics.
[16] D L McShan,et al. The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. , 1992, International journal of radiation oncology, biology, physics.
[17] P C Goodman,et al. Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.
[18] R. Coleman,et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.
[19] K. Geisinger,et al. Positron Emission Tomography in the Evaluation of Laryngeal Carcinoma , 1995, The Annals of otology, rhinology, and laryngology.
[20] C C Ling,et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.
[21] M. Singer,et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. , 1999, Radiology.
[22] R. Tucker,et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C B Caldwell,et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. , 2001, International journal of radiation oncology, biology, physics.
[24] J. Cappellari,et al. Preoperative identification of benign versus malignant parotid masses: A comparative study including positron emission tomography , 1995, The Laryngoscope.
[25] M. Martel,et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. , 1997, International journal of radiation oncology, biology, physics.
[26] J A Purdy,et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.
[27] U. Pietrzyk,et al. Detection of Unknown Primary Cancer with Fluor-Deoxy-Glucose Positron Emission Tomography , 1999, The Annals of otology, rhinology, and laryngology.
[28] M Schwaiger,et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] S U Berlangieri,et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. , 1998, Lung cancer.
[30] K. Geisinger,et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography , 1995, The Laryngoscope.
[31] A. Dowlati,et al. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. , 1997, Thorax.
[32] Tohru Shiga,et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. , 2002, International journal of radiation oncology, biology, physics.
[33] Andrew Jackson,et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. , 2002, International journal of radiation oncology, biology, physics.
[34] L B Marks,et al. The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. , 1995, International journal of radiation oncology, biology, physics.
[35] Joos V Lebesque,et al. Optimizing radiation treatment plans for lung cancer using lung perfusion information. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[36] R Paul,et al. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] T Metens,et al. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. , 2000, Journal of neurosurgery.
[38] K Schnabel,et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.
[39] R. Coleman,et al. Serial FDG‐PET Studies in the Prediction of Survival in Patients with Primary Brain Tumors , 1993, Journal of computer assisted tomography.
[40] J. Matthews,et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. , 2002, International journal of radiation oncology, biology, physics.
[41] Curtis B Caldwell,et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. , 2002, International journal of radiation oncology, biology, physics.
[42] M Schwaiger,et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. , 1998, International journal of radiation oncology, biology, physics.
[43] J. Purdy,et al. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. , 1995, International journal of radiation oncology, biology, physics.
[44] T G Turkington,et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. , 1999, Lung cancer.
[45] M. Bergström,et al. Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. , 1985, Journal of computer assisted tomography.
[46] S Mutic,et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[47] M Schwaiger,et al. First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. , 2000, International journal of radiation oncology, biology, physics.
[48] V Kalff,et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Gerald J. Kutcher,et al. The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer , 2000 .
[50] John L. Humm,et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[51] T G Turkington,et al. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. , 1993, International journal of radiation oncology, biology, physics.